Current Editions
Pharma deals: Demand declines for validated assets
In BioCentury’s third annual pharma deals analysis, bispecifics and degraders are in, cell and gene therapies are out, and China brings more than me-toos
Deals
Product Development
Celldex data question the role of mast cells in EOE
Barzolvolimab meets Phase II endpoint but fails to improve eosinophilic esophagitis symptoms
Rocket’s Danon restart puts spotlight on gene therapy field’s AAV redesign challenge
Rocket resumes its Danon disease gene therapy trial, but the field still needs better ways to balance inflammatory and immunosuppressive risks
BioCentury ISSN 1097-7201